Curcio M, Brindisi M, Cirillo G, Frattaruolo L, Leggio A, Rago V, et al
A randomised controlled trial of exenatide (another GLP-1 receptor agonist) published in 2022 showed no overall benefit for alcohol use disorder compared to placebo, highlighting the need for caution in interpreting preliminary findings
Unlocking the potential: semaglutides impact on Alzheimers and Parkinsons disease in animal models
Tesamorelin is a synthetic 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminus and an extended plasma half-life, FDA-approved as Egrifta for visceral adipose tissue reduction in HIV-associated lipodystrophy
Sarris, J., Kean, J., Schweitzer, I., and Lake, J